Skip to main content

Research

New
History

Explore

Search
Cases
Professionals

Resources

Blog
Pricing
Docs

Sign in Create account

Cases

CourtFilingsPetition dateMore filters

Case

Funded debt

Stage

Exit

Next hearing

Last activity

Petition date

Court

Eiger BioPharmaceuticals, Inc. Professionals

Eiger BioPharmaceuticals, Inc.

Sale Process

Case No. 24-80040·Texas Northern·Petition date Apr 1, 2024

Research this case Track this case Sign in

OverviewHearings Professionals

Professionals

Retained professionals and compensation participants, joined to their source filings.

A

Alvarez & Marsal

Retained · fee applicantChief Restructuring Officer · Debtor

Dkt. 257
Dkt. 150

D

Deloitte Tax LLP

Fee applicant

D

Dundon Advisers LLC

Fee applicant

M

McKool Smith P.C.

Fee applicant

M

Meland Budwick, P.A.

Fee applicant

M

Munsch Hardt Kopf & Harr, P.C.

Fee applicant

N

Neligan LLP

Retained · fee applicantBankruptcy Counsel · Debtor

Dkt. 202
Dkt. 311

P

Porzio, Bromberg & Newman, P.C.

Fee applicant

S

Sidley Austin LLP

Fee applicant

S

SSG Advisors, LLC

Retained · fee applicantInvestment Banker · Debtor

Dkt. 156
Dkt. 258

Judge: Stacey G.C. Jernigan
Petition assets: $10M–$50M
Petition liabilities: $50M–$100M
Industry: Healthcare
Debtors: 5

Eiger BioPharmaceuticals, Inc. is a Palo Alto-based biopharmaceutical company founded in 2008 that develops therapies for rare diseases. The company, which trades on Nasdaq under the ticker EIGR, focuses on first-in-class drugs for conditions with high unmet medical needs. Its flagship product, Zokinvy, is FDA-approved for treating progeria. Eiger operates with nine employees across the U.S. and Europe, relying on contract manufacturing organizations for production and holding significant intellectual property and tax assets.

Case background, summaries, and key terms are generated from the filings on this docket. Docket entries and documents come from the court.

Report a data error